The TRIPS Agreement (Trade-Related Aspects of Intellectual Property Rights) allows countries to issue compulsory licenses to manufacture or import generic versions of patented drugs in certain public health emergencies or other circumstances [41]
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
All anti obesity medications including semaglutide, tirzepatide, and liraglutide, may carry gastrointestinal adverse events such as abdominal pain, decreased appetite, and nausea, and they should be used under close medical supervision, particularly in individuals with a family medical history of thyroid cancer, or existing cardiovascular disease, chronic kidney disease, or risk of heart attack
If you do one thing, lift weights